目的 了解六安市人民医院住院患者注射用辅助用药的使用情况并进行分析与评估，为患者临床合理用药提供参考。方法 选取六安市人民医院2015年1月—2017年12月住院患者注射用辅助用药的相关数据，并对销售金额、用药频度（DDDs）、日均费用（DDC）和排序比（B/A）等情况进行统计分析。结果 2015—2017年注射用辅助用药的销售金额和构成比均逐年下降。神经系统用药的销售金额稳居第1位，中成药（理血剂）的DDDs在2016、2017年均最高。丹红注射液、参芪扶正注射液、鸦胆子油乳注射液的销售金额呈大幅下降趋势，前列地尔注射液、生脉注射液、脑苷肌肽注射液的销售金额呈逐年上升趋势。吡拉西坦氯化钠注射液、注射用血栓通（冻干）和木糖醇注射液的DDDs始终排前5位。丹红注射液和参芪扶正注射液的B/A<1.0外，其余B/A值均>1.0，整体DDC适中。结论 六安市人民医院注射用辅助用药的使用大幅下降，管控成效显著，但仍需对性价比较差的辅助用药进行重点跟踪，进一步促进其合理使用。

Objective To understand the current situation and development trend of adjuvant drugs for injection in inpatients of Lu'an People's Hospital, so as to provide reference for clinical rational use of drugs. Methods The relevant data of adjuvant drugs for injection from January 2015 to December 2017 was collected, and consumption sum, defined daily dose system (DDDs), defined daily cost (DDC), and drug sequence ratio of the adjuvant drug injections were statistically analyzed. Results Consumption sum and constituent ratio of adjuvant drugs for injection from 2015 to 2017 were decreased year by year. Consumption sum of neurological drugs were ranked the first. DDDs of proprietary Chinese medicine (blood-regulating agent) were the highest in 2016 and 2017. Consumption sum of Danhong Injection, Shenqi Fuzheng Injection, and Yadanzi Oil Emulsion Injection showed a sharp downward trend, while consumption sum of Alprostadil Injection, Shengmai Injection, and Cattle Encephalon Glycoside and Ignotin Injection were on the rise had the trend of rising year by year. DDDs of Piracetam and Sodium Chloride Injection, Xueshuantong for injection (freeze-dried), and Xylitol Injection were always ranked the top five. B/A of Danhong Injection and Shenqi Fuzheng Injection were below 1.0, while B/A of others were above 1.0. DDC of adjuvant drug for injections were moderate on the whole. Conclusion The use of adjuvant drugs for injection in Lu'an People's Hospital has dropped drastically, and the effectiveness of management and control is remarkable. However, it still needs to focus on the adjuvant drugs with poor cost performance to further promote their rational use.